

January 05, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Sub : Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer

Ref : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI LODR Regulations**"), we wish to inform you that the Board of Directors ("**Board**") of Thyrocare Technologies Limited ("**the Company**"), upon the recommendation of the Nomination and Remuneration Committee ("**NRC**"), has approved the appointment of **Mr. Rajdeep Panwar** as **Chief Commercial Officer** of the Company, categorised as **Senior Management Personnel**, with effect from **January 05, 2026**.

The aforesaid appointment was approved by the Board by way of a **resolution passed by circulation** on **January 05, 2026 at 11:07 A.M. (IST)**.

In compliance with Regulation 30 of the SEBI LODR Regulations read with **SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**, the requisite disclosure is enclosed as **Annexure – 1**.

The aforesaid disclosures are also being made available on the website of the Company at **<https://investor.thyrocare.com/announcements/>**.

This is submitted for your information and records.

Yours faithfully,
For **Thyrocare Technologies Limited**

Brijesh Kumar
Company Secretary and Compliance Officer



Encl: A/a

Annexure-1

Disclosure under sub-para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/ 0155 dated November 11, 2024

Change in Senior Management Personnel

1.	Name & Designation	Mr. Rajdeep Panwar – Chief Commercial Officer
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment ;	Date of Appointment: January 05, 2026 Term of Appointment: As per the applicable Human Resources policies of the Company relating to superannuation
4.	Brief Profile (in case of appointment)	<p>Mr. Rajdeep Panwar is a senior healthcare and diagnostics industry professional with over 21 years of experience, having led large-scale diagnostic networks, laboratory operations and commercial functions across reputed healthcare organisations.</p> <p>He most recently served as Director – GHIL Pharma & Diagnostics Limited (Medanta Labs), where he led the establishment and expansion of laboratory and pharmacy business verticals across North India.</p> <p>His prior experience includes leadership roles at Apollo Diagnostics, Dr. Lal PathLabs, Ortho Clinical Diagnostics (Johnson & Johnson Group), Quest Diagnostics India Private Limited, Sitaram Bhartiya Institute of Science & Research and Pathnet India Private Limited.</p> <p>Mr. Panwar has extensive experience in P&L management, laboratory network expansion, business launches, digital diagnostics initiatives, NABL/CAP accreditation, LIMS integration and large-scale team leadership, and has played a key role in scaling diagnostic operations across metro and non-metro markets.</p> <p>He holds an M.Sc. in Biochemistry, B.Sc. in Medical Laboratory Technology, a Diploma in Medical Laboratory Technology, and is trained as an Internal Auditor for NABL ISO 15189.</p>
5.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable